QMB Innovation Centre
QUEEN MARY BIOENTERPRISES

Discovery

H1 2023

NEWS, VIEWS AND EVENTS AT QMB

Farewell to Ramsay
PAGE 3

Positive results from influenza human challenge study conducted by hVIVO
PAGE 5

Chancellor unveils £650m 'war chest' for life sciences sector
PAGE 14

Editor's Welcome

Welcome to the Summer 2023 issue of QMB's Newsletter.

In this issue we welcome SpotOn Clinical Diagnostics to QMB and speak to renowned scientists Dr Charles Turner and Prof. Neil Dalton who have been at the forefront of pre-and ante-natal screening for over 30 years.

The techniques they developed at Guy's Hospital when they first got access to tandem mass spectrometry in 1999/2000 went on to form the basis of the work behind the patents on which SpotOn was built. These techniques were widely adopted and are now used to test around 30 million babies a year around the world, saving tens of thousands of lives.

We also speak to Grant Bourhill, the new Managing Director of Barts Life Sciences, a joint venture between Queen Mary University of London and the Barts Health NHS Trust.

Grant's task is to accelerate the latest healthcare innovations from bench to bedside using the unique partnership between Barts Health NHS Trust, Queen Mary University, and the local community.

We also hear from hVIVO, which has successfully manufactured its Omicron human challenge agent, and Meta Materials, which recently notched up its 512th active patent document, of which 322 patents have issued.

We also bid a fond farewell to Dr Ramsay Richmond who has decided to retire after 17 glorious years at QMB.

We're eager to hear your views too, so please share your feedback. For more updates and the latest news from QMB, please visit our website.

Nas

Farewell to Ramsay

This month we bid a fond farewell to Dr Ramsay Richmond after he announced his retirement earlier this year.

Ramsay has been with QMB as Executive Manager for nearly 17 years. During his distinguished career, Ramsay has championed the need for more incubation space in London as well as being a huge advocate for Whitechapel in East London as a life sciences hub.

In his time here, Ramsay has helped countless fledgling SME start-up companies to acclimatise to the world beyond the university laboratory, often guiding them through the design of their incubation space at QMB and advising them on their business plans.

Ramsay will be missed enormously by everyone at QMB, and everyone who had the pleasure to work with him across the wider Queen Mary University of London family.

Nas Hornett, QMB's Operations Manager, now takes on Ramsay's role as Executive Manager.

Nas joined QMB in 2011 as Operations Manager, towards the final phase of QMB's construction, and was responsible for building the operational infrastructure, including procurement, marketing and events, tenant onboarding and lease negotiations.

Nas has played a central role in establishing the QMB brand and has more recently takes on the role of Executive Manager to create and oversee the strategic direction of QMB and QME.

Like Ramsay, Nas is passionate in helping Life Science start-ups establish and grow their ventures through innovation and entrepreneurship.

Nas said: "Ramsay has made an enormous contribution to QMB and the Queen Mary University of London. Every company that has come through our facility has benefitted from his help and guidance. He has been an incredible colleague to work with and we all wish him well in his retirement."

hVIVO plc successfully manufactures Omicron human challenge agent

hVIVO plc, a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has successfully manufactured its Omicron human challenge agent.

The news brings the Company's unique portfolio of human challenge models to 11, subject to the successful completion of the characterisation study, and receipt of relevant regulatory approvals.

hVIVO's human challenge models test a broad range of infectious and respiratory disease products, and offers Omicron human challenge trials as part of its service offering.

The company is currently in discussions with a number of existing and potential customers.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row.

DR ANDREW CATCHPOLE

The Company has world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

Positive results from influenza human challenge study conducted by hVIVO

hVIVO plc says it has noted an announcement by Cidara Therapeutics which reported positive interim results from an ongoing human challenge study testing CD388.

hVIVO is conducting the Phase 2a single-center, randomised, double-blinded, placebo-controlled trial using its H3N2 Influenza Human Challenge Study Model, while CD388 is Cidara's long-acting drug-Fc conjugate antiviral for the treatment of seasonal influenza.

The interim analysis is based on 56 healthy volunteers, with 28 receiving a single dose of CD388 (150 mg) and 28 receiving a placebo. All subjects were then challenged with a H3N2 influenza A challenge agent.

Interim results showed a decrease in viral replication in the upper respiratory tract and influenza infection in participants receiving a single dose of CD388 when compared to placebo.

hVIVO has three decades of experience and expertise in safely conducting challenge studies across a range of respiratory viruses, including various strains of influenza, respiratory syncytial virus (RSV), human rhinovirus (HRV - common cold virus), COVID-19, asthma, as well as malaria.

Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, said: "The results are another clear demonstration of the value of human challenge trials in delivering quick efficacy data, de-risking entry into later stage clinical development."

QMB creates space for SpotOn Clinical Diagnostics to expand

DR CHARLES TURNER

PROF NEIL DALTON

Renowned scientists Dr Charles Turner and Prof. Neil Dalton have been at the forefront of pre-and ante-natal screening for over 30 years. The technology and protocols that they developed and patented now form the basis of SpotOn Clinical Diagnostics, one of QMB's newest tenants.

Founded in 2011, SpotOn Clinical Diagnostics uses mass spectrometry to rapidly screen patients for inherited and acquired clinical conditions from a single dried blood spot. Mass spectrometry is a highly sensitive technique which can analyse proteins, enzymes and metabolites in the blood without the need for large liquid samples. This is especially important when screening young children for inherited metabolic disease and new-born babies for sickle cell disease.

All babies born in the UK – 694,685 in 2021 – are screened for sickle cell disease and other clinically significant haemoglobinopathies (abnormalities in haemoglobin within the blood). Other methods for ante-natal screening for sickle cell disease and thalassaemia use fresh liquid blood samples, which are more expensive to process, store and transport.

The method can also be used in the early detection and clinical monitoring of chronic health problems, including kidney and heart disease and diabetes, as well as for rapid diagnosis of a wide range of diseases in acutely ill children admitted to intensive care with life-threatening symptoms.

Dried urine spots can also be used for the very early detection of kidney disease.

The test works by converting proteins to peptides and then using a mass spectrometer to select and accurately measure diagnostic metabolites and/or peptides.

SpotOn Clinical Diagnostics was spun out of Kings College London and the Evelina Children's Hospital.

The patents on which SpotOn Clinical Diagnostics was founded were filed around 2006 by Prof Dalton and Dr Turner, a clinical biochemist, who were working at Guy's and St. Thomas's NHS Foundation Trust.

The pair have worked together since the late 1970s, first at Guy's and then the Evelina Children's Hospital. Prof Dalton eventually moved across to academia where he rose to the position of professor of paediatric biochemistry at King's College London.

The techniques that they developed at Guy's when they first got access to tandem mass spectrometry in 1999/2000, which went on to form the basis of the work behind the patents on which SpotOn was built, went largely unacknowledged but were widely adopted and are now used to test around 30 million babies a year around the world, saving tens of thousands of lives.

Because of this wide uptake, the next time they had a bright idea the medical school was very keen that they should patent it to ensure that the Trust and the University could benefit from the research that they were doing, rather than just outside testing companies.

The company was formed in 2011, with shares owned by King's College, Guy's and St Thomas's, Prof Dalton, and Dr Turner.

SpotOn was profitable from the start by diversifying into a range of other types of testing, mainly for research projects to keep the company afloat, as gaining approval for its neonatal screening tests by the National Screening Committee was a slow process.

NHS Wales was SpotOn's first newborn screening customer and, after a successful first trial in 2009 involving 40,000 babies, NHS England agreed to approve it as one its tests after another large study of more than 20,000 babies was conducted in 2016. The majority of labs in the UK now use SpotOn's screening tests, as well as six labs in Germany.

The move to Queen Mary Bio-enterprises' (QMB) Innovation Centre was prompted by SpotOn's need for more space. They were previously in a very crowded NHS research and diagnostic lab embedded right in the middle of the Evelina London Children's Hospital.

In order for SpotOn to get EU IVDR (In Vitro Diagnostic Regulation) and UK MHRA (Medicines and Healthcare products Regulation Agency) accreditation, it needed to move as the previous facilities were not accreditable as they were.

"We are at a point in life where we need to concentrate on the core business and not concentrate on all the other things that we do," Dr Turner said.

QMB offered great facilities in a good location at the right price, he said.

Looking to the future, SpotOn will be targeting India and the Philippines, which are attractive markets because of their high birth rates and interest in certain inherited conditions, namely beta thalassemia (India) and thalassemia haemoglobin E (Phillipines).

In Africa, where sickle cell anaemia is endemic, insecure power supplies mean that it would be difficult to establish testing centres but, because dried samples can easily be posted in, it can still service those markets.

New Barts Life Sciences' MD has big plans for the future

Grant Bourhill, the newly-installed Managing Director of Barts Life Sciences, a joint venture between Queen Mary University of London and the Barts Health NHS Trust, has big plans.

GRANT BOURHILL

He is the former CEO of Surrey Research Park and Leicester Science Parks and has a wealth of experience in the innovation, real estate and research sectors, industry and academia. He is also a non-executive director of the UK Science Park Association.

Just a few months into the role and Grant is clear about what he has to do: build a globally significant life sciences cluster of companies in Whitechapel that will transform healthcare locally, nationally and globally, and transform the economic opportunities available in East London.

Accelerating the latest healthcare innovations from bench to bedside is possible, he says, because the unique partnership between an NHS trust, a research-intensive university and the local community makes Whitechapel a great place to set up a business.

The Scot has had a storied career, both north and south of the border.

Having received his PhD in physical chemistry from the University of Strathclyde where he researched the response of materials to lasers, Grant headed west to the USA where he worked at NASA on novel materials for sensing. He came back to the UK and worked for a defence research organisation.

Having made a shift away from materials into optics, he left the defence sector for a career in the commercialisation of optical devices and systems, joining the Sharp Corporation Research Base south of Oxford, where he was responsible for new technology introduction. The no-glasses Nintendo 3D displays came out of this work as did automotive dual-view displays where, on a single display in the centre of automotive consoles, the driver can see full screen GPS, but the passenger can watch full-screen movies through the internet. That made its way into a range of high-end vehicles across a number of brands.

After this successful stint in industry, he joined a clean tech company looking to introduce new low carbon services into domestic homes – a highly regulated area where he needed to work closely with government, industry and academia.

It was a natural next step to start to move to Leicester, Guildford and, now, Whitechapel, to bring all this experience together to create innovation-focussed place-based transformation that could bring industry closer to academia and regulators.

Success with this, whether it be the space sector up in Leicester or the life sciences cluster at Whitechapel, shares common underpinnings.

First of all, you ideally need a solid anchor institution. Whitechapel has two in strong partnership - Barts Health NHS Trust, the biggest in the country, and Queen Mary University, one of the UK's most prolific research institutions, that have the drawing power to attract other organisations to establish themselves in the area.

While anchor institutions are important, so too is the social ambition and Barts Life Sciences is determined to transform local economic opportunities in East London.

Companies want ready access to talent and Grant said it was very important to, as far as possible, hire locally so that the economic benefits can stay within the local community.

"It's absolutely crucial that the local community are integrated, not just engaged but actively involved in everything that's happening. So they're involved in the construction, they're involved in the operation, they're involved in the research, and the local community can really feel the benefits of the life science cluster," he said.

This means that Grant and his team must offer an effective skills escalator with a schools outreach, training for apprenticeships at all levels, and enable people to move from one profession to another.

They have already launched something called Barts Health Futures Hub at Newham College, which provides a range of training for people in healthcare and life sciences.

“That’s just one example that we can scale to prepare the local community for the workforce needs of the future,” said Grant.

Still, as ambitious and as optimistic as he is, Grant does acknowledge the size of the challenge he’s facing.

This includes making sure that they can quickly accelerate and scale the type of innovation that will make a difference for healthcare and, ultimately, for people’s lives. To have a critical mass of companies, they also need a critical mass of real estate and there is a need to now further grow partnerships ahead of real estate becoming available.

“There are lots of other areas nationally as well as globally which are also developing life science clusters, so there’s an element of speed that’s now needed,” said Grant.

The benefits of this life sciences cluster to companies already part of Queen Mary BioEnterprises Innovation Centre (QMB) are that it provides room for them to grow within an established and well-supported ecosystem.

Secondly, they can fill the cluster with their supply chain. And thirdly, they’ll have a huge amount of talent next door that will then help their growth.

Also fuelling growth will be the University’s two new cross-faculty institutes, one focused on precision healthcare - the Precision Healthcare University Research Institute (PHURI), and one focused on the digital environment, the Digital Environment Research Institute (DERI).

“And those are exactly the areas that are going to support, from an academic perspective, the life sciences cluster,” said Grant.

Asked about the difficulty of attracting companies to the UK rather than, say, the USA or EU, Grant says that he’s starting from the base where UK companies attract the greatest amount of funding compared to any other country in Europe.

“We’re in a reasonably strong position but US investment dominates and, globally, competition is fierce,” said Grant.

Ultimately, Grant believes he will know that he has succeeded when he has a deck of case studies of health interventions that have really impacted in a positive way the local population and have then been scaled more widely. Also, there will be people nationally and internationally contacting Barts Life Sciences saying they want to move in because of the strength of the organisations that are there.

QMI-backed start-up a hair's breadth away from revolutionising endoscopy

Endoscopy is a widely used, but currently limited, medical procedure which involves inserting a flexible tube with a light and a camera attached to it to affected parts of the body. It is used to visualise and examine the gastrointestinal tract, respiratory system, and other hollow organs.

During an endoscopy, the endoscope is inserted through a natural body opening or a small incision made for the purpose of the procedure. The endoscope allows the healthcare professional to view the internal organs or structures in real-time on a monitor.

However, current endoscopes are too thick to enter very small spaces like joints, cardiac arteries, and blood vessels in the brain.

This has created an opportunity for a minimally invasive endoscope using a single fibre, or about as thick as a human hair, and one developed by QMI-backed start-up Pryfiber.

In addition to providing a faster and more accurate diagnosis and therapy monitoring, microendoscopy can offer in vivo diagnosis as opposed biopsies.

DR LEI SU

The problem that Dr. Lei Su, Reader in Photonics at Queen Mary University, and the founder of Pryfiber, found is that single-fibre technology faces a flexibility problem: when the endoscope bends, the light mixes in the single fibre and the formed image is scrambled and therefore useless.

Dr. Su began working on the problem of the single fibre endoscope in 2014. The Pryfiber endoscope aims to tackle the flexibility problem and has a resolution as low as less than one micrometer, meaning that it can be used to look at a single cell. Alongside the endoscope, Pryfiber will develop an algorithm that will enable real-time imaging and diagnosis.

He says that the technology also has non-medical applications too. It can be used for material characterisation and civil engineering when they need to explore extremely small cavities

Funding for the business came from NLC, the European healthtech venture builder, QMI, Dr. Su and the CEO, Thomas Vargoczky.

QMI has played a very significant role in the commercialisation, providing impact acceleration funding to give Dr Lei the essential resources needed to develop the technology.

He rates East London as a great place for start-ups, saying that its multicultural, very international and a great place for business.

Other products he is working on with QMI include wearable sensors for cardiovascular monitoring and optoelectronic devices made of single-crystal perovskites.

For more information, please visit **pryfiber.health**

ROEX mixing it up with QMI

Over the past few decades, technology has given music producers the power to do some amazing things that would have once been unimaginable.

Automatic tools like dynamic range compression, which was originally developed so that someone didn't have to move the volume up and down throughout the recording process, have become the norm.

These tools get used creatively and despite fears that jobs will be lost because of them, demand for the people who can do the production is higher than ever before.

For some time, there have been tools to help with mastering – the various processes applied to the stereo mix, such as equalisation, compression, and stereo enhancement to get the music ready for release – but, until now, mixing – the process of combining multiple audio tracks together to create a cohesive and balanced stereo or surround sound mix ready for mastering – has had to be done manually.

QMI-backed startup RoEx uses state-of-the-art audio signal processing and machine learning algorithms to intelligently mix audio. Based on years of research and development (R&D), user testing, and market research the company puts the power of music production into everybody's hands.

The RoEx filter, after which the company is named, is a type of auditory filter that the brain uses to process sounds and turn them into a set of frequencies that can be understood in the brain.

The company is driven by the research done by Dave Ronan, the co-founder and CEO of RoEx, when he was a student at the university.

The research was guided and supported by Prof. Josh Reiss, a QMU academic and serial entrepreneur, who had commercialised many similar projects in the past. Funding was provided by Haatch Ventures, a pre-seed and seed fund that invests in software companies, and QMI. Haatch and the QMUL Investment Fund invested £420k for growth and product development.

Prof. Reiss says that what RoEx does is transformative and disruptive and has no real competitors.

He said: "We reached a point a few years ago where there was probably more music being mastered with the intelligent tools than mastered by hand by mastering engineers. We may reach that point with mixing with RoEx.

DAVE RONAN

PROF JOSH REISS

"It's important to note though that that does not mean that we would be doing away with the job… music production continues to grow and so it's a net positive for the industry."

The fact that another tool is available is good for the music industry as a whole as huge amounts of content that would not be mixed due to high costs can now be.

"It's important to do it right, to do it well. If more music is being mixed, we don't want it to be mixed badly. We want to offer the tools and technologies in the best way, so that they are assistive, not deconstructive. They must assist, not annihilate," he said.

QMI and Queen Mary University have been tremendously helpful in getting RoEx off the ground, Prof. Reiss said. Firstly, it started out as a university intellectual process: it would not be possible to commercialise this without the university's support and approval.

Queen Mary was very helpful with commercialising its IP and very positive about promoting it. It worked with the team on drafting patents and securing a patent attorney. QMI sits on the board of the company to offer advice and support. They also helped secure the funding and assisted with drafting, preparing, and submitting grants applications.

RoEx is based in the Queen Mary Enterprise Zone within QMB.

For more information, please visit **roexaudio.com**

Meta Materials reaches 500 patent milestones

QMB tenant Meta Materials Inc., an advanced materials and nanotechnology company, recently added another U.S. patent to its impressive roster with the addition of a lithium battery patent that utilises novel separators including, but not limited to, nanoporous ceramic NPORE® separators.

META now has a total of 512 active patent documents, of which 322 patents have issued.

META is developing innovative materials to help inhibit battery fires, make batteries safer and more efficient, as well as extend vehicle range and make battery supply chains more sustainable.

“Battery fires continue to be a common problem across all applications, from mobile devices to e-bikes and EVs. Both of our new products have features that help prevent thermal runaways,” said George Palikaras, President and CEO.

Dr. Shann Kerner, META’s Chief Intellectual Property Officer, added: “To protect our broad range of technology platforms, products, and manufacturing technologies, META continues to grow its IP portfolio. We now have 512 active patent documents, across 127 patent families, of which 69 include at least one issued patent.”

DR SHANN KERNER

Meta Materials signs joint development agreement with global OEM

Meta Materials has also signed a joint development agreement for NPORE® battery separator materials with a confidential global Top 10 battery OEM.

NPORE® is a free standing, flexible separator which is made with a ceramic nanomaterial that provides best-in-class dimensional stability with less than 1% heat shrinkage up to 220° C, to help inhibit thermal runaway.

Conventional plastic separators significantly shrink at elevated temperatures, which can cause thermal runaway and battery failures. NPORE® features pore sizes less than 100 nanometers, with a very narrow pore size distribution. META is able to tailor the properties of the separator by changing its thickness, porosity, and size of the pores.

“We are excited to see our battery team led by Dr. Steve Carlson, who has spent two decades pioneering technologies to make batteries safer, partnering with one of the top battery OEMs in the world to jointly develop and adapt NPORE® as a separator solution,” said George Palikaras, President and CEO of META.



DR STEVE CARLSON

CHANCELLOR JEREMY HUNT

Chancellor unveils £650m 'war chest' for life sciences sector

Chancellor Jeremy Hunt announced a £650m "war chest" alongside a promise to fire up the UK's life sciences sector by shaking up planning rules and encouraging investment.

The funding package, dubbed 'Life Sci for Growth', brings together 10 different policies and is the latest effort from government to deliver the prime minister's pledge to turn the UK into a "science superpower".

Around £250m will be committed to incentivising pension schemes to invest in emerging science and technology companies, while changes will be made to planning rules to free-up lab space.

Funding will go towards the rail project connecting Oxford and Cambridge, while £154m will go towards increasing the capacity of the UK's biological data bank.

The package will also see £121m, consisting of both new and existing funding, go towards speeding up clinical trials and improving access to data and nearly £50m pledged towards preparations for future health emergencies.

Announcing the news, the chancellor said life sciences was "one of the UK's most successful sectors" and was worth over £94bn to the UK economy in 2021.

"Our life sciences sector employs over 280,000 people, makes £94bn for the UK each year and produced the world's first Covid vaccine," Hunt said.

"These are businesses that are growing our economy while having much wider benefits for our health – and this multi-million-pound investment will help them go even further."

The policy announcements were informed by a recent independent review by former health minister Lord O'Shaughnessy, and also come after a review by Dame Angela McLean on the UK life science regulatory system.

Science and technology secretary Chloe Smith added: "Backing our life sciences sector is a double win for the UK. The package we are announcing today won't just help this £94bn industry drive more economic growth and create more high-skill jobs.

"It will support advances in public health, which will mean we can all have happier, healthier, more productive lives, delivering a virtuous circle of benefits to society and the economy."

Experts have welcomed the new funding and government focus on the sector, with Professor Andrew Morris, director of Health Data Research, calling the investment in infrastructure and new public-private partnerships "good news" for the sector.

Dame Kate Bingham, managing partner of SV Health Investors, said: "Great to see that the government has addressed some of the concerns raised by the life sciences sector to solve several key roadblocks to unlock the huge health and economic opportunities created by life sciences innovation.

"Collectively, these moves will enable life sciences and biotech companies to grow and flourish, to explore and ultimately bring much-needed treatments to patients who need them."

Nicholas Galakatos, global head of life sciences at Blackstone, which has invested in life sciences businesses, said it welcomed more support for the sector.

"The UK is at the forefront of innovation in life sciences, but companies need access to capital at scale and resources so they can bring transformational therapies from the lab to the patient," he said.

Life sciences secures £2.45bn investment in golden triangle during 2022

Investment into life sciences real estate exceeded £2.45bn in the 'golden triangle' in 2022, according to a report from Cushman & Wakefield.

The firm's Life Sciences Golden Triangle Lab Report showed that demand for purpose-built life sciences space in Cambridge, Oxford and London, also known as the golden triangle, remained "extremely strong" in 2022 despite supply shortages.

Investment appetite in the golden triangle remained strong compared with previous years, despite retracting since 2021 levels.

The first half of the year accounted for 65% of total activity for the year with a dip in the second half due to economic headwinds affecting wider market conditions.

Venture capital investment in real estate was the highest on record, bar 2021, ending 22% higher than 2020 levels.

Cushman & Wakefield expects to see sustained investment interest throughout the year.

Fundamental drivers such as increased healthcare spending, the UK's ageing population and government investment in innovation and scientific research will continue to attract investment.

The report also found that, despite strong levels of investment, supply has failed to keep pace with demand, and a lack of quality labs has raised headline rents with modest take-up levels, limiting leasing success last year.

As a result, 2022 saw more value-add, development and repurposing activity, aiming to address the issues with current available stock to better serve the occupational market.

Supply increased by 350,000 sq ft in 2022, with a further 2m sq ft of development expected to start in 2023-24.

However, Cushman & Wakefield added that demand would continue to outstrip supply until 2025-26, when approximately 4m sq ft of supply is set to be delivered and the greatest proportion of occupational demand will be met.

London saw the most take-up last year (39%) out of all golden triangle locations, which followed a record year in 2021.

Deals such as the pre-let to MSD in King's Cross and the letting at Rolling Stock Yard at £110/sq ft for a fitted lab were responsible for the lead over Oxford and Cambridge in 2022.

Although particularly high take-up was recorded in London, success was echoed across the entire golden triangle, with leasing take-up reaching 635,866 sq ft in 2022. All markets saw rents rise to new highs with 10% to 20% year-on-year growth, with Cambridge leading the way at 18.2% annual growth.

Michael Aston, head of life sciences at Cushman & Wakefield, said: "Demand for life sciences real estate continues to grow, while the supply of high-quality stock will remain out of kilter for some years to come.

"A lot of venture capital and big pharma money is waiting on the touchline to access the best biotech investments, while pension funds, sovereign wealth funds and other buckets of capital are queued up to invest in life sciences real estate.

"The UK's golden triangle continues to grow as Europe's innovation super-cluster, with London poised to come into its own in the coming years as companies large and small take up newly delivered space."

PLEASE CONTACT OUR MANAGEMENT TEAM
WITH ANY FEEDBACK OR NEWS STORY IDEAS:

Nastaran Hornett

EXECUTIVE MANAGER

Sheryl Malloy

OPERATIONS MANAGER

For further information, or to enquire about our services, please contact:

The QMB Innovation Centre
42 New Road, London, E1 2AX

+44 (0) 20 7882 8950
qmb-innovation-centre@qmul.ac.uk
QMBInnovation

QMBIOENTERPRISES.COM

Queen Mary Innovation

Queen Mary University of London